Vertex cystic fibrosis drugs shown to boost lung function, shrs rise

May 1 (Reuters) - Vertex Pharmaceuticals Inc on Thursday said a combination of its cystic fibrosis drug Kalydeco with an experimental compound was shown to improve lung function in a mid-stage trial, and its shares rose 10 percent after the news.